Nadim Ahmed Buys Shares of Disc Medicine, Inc.
Nadim Ahmed purchased 5,176 shares of Disc Medicine, Inc. on June 18, 2026.
Key Points
- Nadim Ahmed bought 5,176 shares of Disc Medicine, Inc. on June 18, 2026.
- Shares of NASDAQ:IRON traded near $70.8 on Wednesday with a market cap of $2.7 billion.
- Analysts maintain a strong buy consensus with a target mean price of $101.55.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Nadim Ahmed purchased 5,176 shares of Disc Medicine, Inc. (NASDAQ:IRON) on June 18, 2026. This insider buy was not part of a planned trading program. The stock traded around $70.8 on Wednesday.
Insider Buying and Selling at Disc Medicine, Inc.
In addition to Nadim Ahmed's recent purchase, several other insiders were active on June 18, 2026. Liam Ratcliffe also bought 6,212 shares, while Rahul Khara, the Chief Legal Officer, acquired 7,500 shares at an average price of $14.69. Meanwhile, John Quisel, the CEO, sold 34,000 shares under a planned selling program at a price of $70.22, but also made a non-planned purchase of the same amount at $9.86.
Disc Medicine, Inc. Stock Down 11.5%
Shares of Disc Medicine, Inc. traded near $70.8 on Wednesday. The company has a market capitalization of approximately $2.7 billion. The stock's forward P/E ratio is not meaningful as the company is not currently profitable. Disc Medicine has a beta of 2.101, indicating it is more volatile than the overall market. The stock's 52-week range is between $40.0 and $99.5, with a 50-day moving average of $68.55 and a 200-day moving average of $73.16. The company maintains a strong liquidity position with a current ratio of 24.002 and a quick ratio of 23.446.
$IRON stock price
Daily closing prices, year to date. Not investment advice.
Analysts Set New Price Targets
On June 16, 2026, Morgan Stanley maintained its buy rating on Disc Medicine with a price target of $85. Other firms such as Wells Fargo and Truist Securities have also kept their buy ratings, with price targets of $79 and $83 respectively. Analysts' consensus is a strong buy, with the stock's mean target price at $101.55 based on 11 opinions.
About Disc Medicine
Disc Medicine, Inc., headquartered in Watertown, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing treatments for serious blood disorders. Founded in 2017, the company targets diseases related to red blood cell formation and function. Its pipeline includes bitopertin for various types of anemia, DISC-0974 for anemia in myelofibrosis and chronic kidney disease, and DISC-3405 for polycythemia vera. Disc Medicine employs 154 people under the leadership of CEO Dr. John D. Quisel.
Bottom Line
Nadim Ahmed's insider purchase of Disc Medicine shares signals interest in the company's potential. Investors often track such moves from insiders to gauge confidence in the company's prospects. Disc Medicine's stock remains volatile, reflecting its developmental stage in the biotechnology sector. Analysts continue to show strong support with buy ratings and high target prices.
Get Disc Medicine, Inc. alerts
New 13F filings, insider trades, and analyst moves on $IRON, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.